Loading clinical trials...
Loading clinical trials...
The purpose of this study was to investigate a medicine for the treatment of symptoms and complications of neurogenic detrusor overactivity (NDO) in children and adolescents.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Astellas Pharma Europe B.V.
NCT05491525 · Neurogenic Detrusor Overactivity
NCT02526979 · Overactive Bladder, Neurogenic Detrusor Overactivity
NCT01981954 · Neurogenic Detrusor Overactivity, Pediatric
NCT01539707 · Overactive Bladder, Neurogenic Detrusor Overactivity
NCT04452838 · Neurogenic Detrusor Overactivity
Site US1008
Tarrytown, New York
Site US1010
Cincinnati, Ohio
Site BE3201
Ghent
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions